Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancerMichelle K. Greene, Christopher J. Scott|British Journal of Cancer|2020Cited by 19